Utafiti huu umechunguza ikiwa lipopolysaccharide (LPS) na endospores za Bacillus subtilis (BSS) zinazotolewa kupitia pua hupunguza mwitikio wa anaphylaxis unaoendeshwa na IgE katika panya dume, na ni kwa utaratibu gani wa seli athari hii hutokea. Panya wa wiki sita hadi kumi walipewa LPS au BSS ndani ya pua kwa siku mbili; kisha passive systemic au passive cutaneous anaphylaxis ikachochewa. Dozi ya 4 µg/kg ya LPS na 1 × 10⁷ CFU/panya ya BSS ilipunguza vipimo kama kushuka kwa joto la mwili, kiwango cha plasma mast cell protease-1, kuvuja kwa Evans blue nje ya mishipa na uvimbe wa sikio. Ukubwa wa athari katika grafu ulionekana kuwa karibu na kundi la 2 mg/kg dexamethasone iliyotolewa kwa mdomo. Hata hivyo, utafiti haukubuniwa kama jaribio rasmi la usawa au ubora.

Majaribio ya kijeni na kifamasia yalionyesha kwamba athari ya kinga ilitegemea kipokezi cha interferon aina ya I, IFNAR. Katika panya wasio na IFNAR1, LPS na BSS hazikupunguza dalili za anaphylaxis. Watafiti wanapendekeza kwamba LPS na BSS huchochea uzalishaji wa IFN-α/β; hali hii hupunguza usemi wa jeni Cyp51a1 na Hmgcr katika mast cells, hupunguza non-sterol isoprenoids katika mevalonate pathway na kuvuruga cortical F-actin rearrangement inayohitajika kwa mwendelezo wa FcεRI signaling.

Utaratibu haujapimwa moja kwa moja kwa ukamilifu. Katika utafiti, viwango vya protini za IFN-α/β, kiasi cha lanosterol, intracellular isoprenoid pool, protein prenylation, kiasi cha HMGCR protein, live-cell dynamics za cortical F-actin au calcium flux havikupimwa moja kwa moja. Mechanistic chain inategemea tafsiri ya pamoja ya gene expression, IFNAR deficiency, matumizi ya terbinafine, mevalonate-pathway intermediates, histology na reversal experiments zilizofanywa kwa cytochalasin D.

BSS ilizalisha transcription ya chini zaidi ya Il-6 na Il-1β kuliko LPS huku ikizalisha mwitikio ulio wazi zaidi wa Ifn-α4 na Ifn-β1. Ingawa finding hii inaashiria cytokine profile inayoweza kuwa nzuri zaidi kwa BSS, si ushahidi wa usalama kwa binadamu. Utafiti haukutathmini long-term toxicity, repeated intranasal administration, tissue distribution ya spores, germination risk, immunogenicity, microbiome effect au clinical anaphylaxis treatment.

Swali kuu la utafiti ni lipi?

Swali kuu la utafiti ni ikiwa vichocheo viwili tofauti vinavyoweza kupatikana kutoka mazingira ya vijidudu kupitia njia ya hewa vinaweza kufanya mast cells ziwe na mwitikio mdogo zaidi kwa kiwango cha mfumo mzima. Watafiti walitumia lipopolysaccharide, sehemu ya bakteria Gram-negative, na endospores sugu za bakteria Gram-positive Bacillus subtilis kama modeli mbili tofauti za microbial exposure.

Hoja ya kuanzia ya utafiti ni “farm effect”, inayohusishwa na kuonekana kwa kiwango cha chini cha baadhi ya magonjwa ya mzio kwa watoto wanaokulia katika mazingira ya mashamba. Hata hivyo, utafiti haukuchunguza mazingira halisi ya shamba, watoto au natural environmental exposure. LPS na endospores zilizozalishwa maabara kutoka strain maalum ya B. subtilis zilitumika katika controlled mouse experiments. Kwa hiyo, matokeo haya hayawakilishi athari ya microbial diversity yote katika mazingira ya shamba.

Kwa nini mast cells ni muhimu katika anaphylaxis?

Mast cells ni seli za kinga zenye high-affinity IgE receptor FcεRI kwenye uso wao. Antigen iliyofungamana na IgE inapofanya cross-linking ya molekuli za FcεRI, multistep signaling network huanza ndani ya seli. Mtandao huu huwezesha calcium entry, cytoskeletal changes na usafirishaji wa granules kuelekea cell membrane.

Katika mchakato unaoitwa degranulation, histamine, proteases na mediators wengine wa kibayolojia hutolewa nje ya seli. Dutu hizi zinaweza kuchangia kuongezeka kwa vascular permeability, tissue edema, mabadiliko ya blood pressure na kushuka kwa joto la mwili katika systemic reactions. Utafiti ulijaribu hypothesis kwamba LPS na BSS hubana hatua ya mast-cell degranulation badala ya kufanya mishipa iwe less responsive moja kwa moja baada ya mediators kutolewa.

Passive anaphylaxis model inamaanisha nini?

Katika utafiti, haikutarajiwa kwamba wanyama wangekuwa naturally sensitized kwa allergen. Panya walipewa kwanza anti-DNP IgE antibody maalum kwa dinitrophenol, kisha reaction ikachochewa kwa kutumia bovine serum albumin iliyounganishwa na DNP. Method hii inaitwa “passive” anaphylaxis kwa sababu allergen-specific IgE hutolewa kutoka nje badala ya kuzalishwa na mfumo wa kinga kadiri muda unavyopita.

Model hii hurahisisha kuchunguza mast cell–IgE axis kwa hali zinazodhibitiwa. Hata hivyo, sensitization, T- na B-cell responses, mucosal barriers, microbiome na allergens tofauti zinazohusika katika natural food allergy, asthma, atopic dermatitis au human anaphylaxis haziwakilishwi kikamilifu katika model.

Endospores za Bacillus subtilis ziliandaliwaje?

Watafiti walitumia strain ya Bacillus subtilis KCTC 1021. Bacterial colony moja ilihamishwa kwenye 5 mL Luria–Bertani medium na kukuzwa usiku kucha katika 37 °C kwa shaking ya mizunguko 200 kwa dakika. Siku iliyofuata culture ilipunguzwa kwa uwiano wa 1:100 katika fresh medium na kukuzwa hadi optical density katika 600 nm kufikia 0,6–0,8.

Ili kuanzisha sporulation, bakteria zilihamishwa kwenye sporulation medium yenye nutrient broth, KCl na MgSO₄·7H₂O. Baada ya sterilization, 1 mM Ca(NO₃)₂, 10 µM MnCl₂ na 1 µM FeSO₄ ziliongezwa kwenye medium. Cultures ziliwekwa katika 37 °C na 200 rpm kwa saa 24–48.

Katika phase-contrast microscopy, mature spores zilitathminiwa kama bright refractile structures, huku vegetative bacteria zikionekana kama dark cells. Sporulation rate ilipozidi %90, cultures zilifanyiwa centrifugation katika 4 °C kwa nguvu ya 4.000 × g kwa dakika 15. Cell pellet ilioshwa mara tatu kwa sterile water, ikapashwa katika 65 °C kwa dakika 30 ili kuondoa remaining vegetative cells, na ikaoshwa mara mbili zaidi.

Kiasi cha spores kiliamuliwa kwa serial dilution na colony-forming-unit counting. CFU inamaanisha “colony-forming unit” na inawakilisha makadirio ya idadi ya viable units zinazoweza kuunda colony kwenye suitable culture medium. Spores zilizoandaliwa zilihifadhiwa katika sterile PBS au maji katika 4 °C.

Jaribio la systemic anaphylaxis lilifanywaje?

Panya walipewa PBS, LPS au BSS ndani ya pua mara moja kwa siku kwa siku mbili. Kundi la positive comparison lilipewa dexamethasone kwa mdomo. Katika siku ya pili ya administration, panya walipewa 3 µg anti-DNP IgE kwa njia ya mshipa. Siku iliyofuata, 80 µg DNP-BSA ilitolewa kwa mshipa ili kuchochea systemic anaphylaxis.

Dakika 30 baada ya antigen administration, rectal temperature ilipimwa; saa moja baadaye damu ilichukuliwa na plasma mouse mast cell protease-1 level ikaamuliwa kwa ELISA. MCPT-1 ilitumika kama mojawapo ya systemic biological markers za mast-cell degranulation.

Dexamethasone dose ilichaguliwa kuwa 2 mg/kg. Waandishi wanaeleza dozi hii, kwa kutegemea utafiti wa awali, kama highest dose isiyosababisha lymphopenia. Katika utafiti wa sasa lymphocyte count haikupimwa tofauti.

Jaribio la cutaneous anaphylaxis lilifanywaje?

Katika passive cutaneous anaphylaxis model, 3 µg anti-DNP IgE ilitolewa moja kwa moja ndani ya ngozi ya sikio la panya. Siku iliyofuata 80 µg DNP-BSA pamoja na 2,5 mg Evans blue zilitolewa kwa njia ya mshipa.

Evans blue hufungamana na protini katika damu. Vascular permeability inapoongezeka, dye hutoka nje ya mishipa na kujikusanya katika tissue. Dakika 60 baada ya antigen administration, ear thickness ilipimwa kwa digital caliper; dye katika ear tissue ilitolewa usiku kucha ndani ya 500 µL DMSO na absorbance ikapimwa katika 620 nm.

Jaribio hili lilitoa matokeo mawili yanayokamilishana: ongezeko la ear thickness liliwakilisha edema, huku Evans blue signal ikionyesha kuvuja kwa fluid na protein nje ya mishipa.

LPS na BSS zilibadilishaje vipimo vya anaphylaxis?

Ujumbe mkuu wa Kielelezo 1 ni kwamba LPS na BSS zote zilipunguza systemic na cutaneous anaphylaxis measures kadiri dozi ilivyoongezeka. Katika untreated antigen group, rectal temperature ilishuka hadi takribani 34 °C, huku dozi ya 4 µg/kg LPS na 10⁷ CFU/panya BSS ikidumisha joto karibu 36 °C kwenye grafu. Values hizi zimesomwa takribani kutoka kwenye figure; full numerical table ya group means haijatolewa katika maandishi ya utafiti.

Plasma MCPT-1 level ilikuwa takribani 10–12 ng/mL katika untreated anaphylaxis group na ikashuka hadi takribani 4–7 ng/mL katika effective LPS na BSS doses. Katika cutaneous model, Evans blue signal na ear thickening pia zilipungua kwa uwazi.

Grafu zinazoonyesha 0,4, 4 na 40 µg/kg kwa LPS; na 10⁶, 10⁷ na 10⁸ CFU/panya kwa BSS zinaunga mkono kwamba effect iliongezeka pamoja na dose. Watafiti walitafsiri athari ya 4 µg/kg LPS na 10⁷ CFU/panya BSS kuwa sawa kwa mwonekano na 2 mg/kg dexamethasone.

Kauli ya “athari sawa” inategemea comparison ya effect magnitudes na significance results kwenye grafu. Utafiti haujumuishi formal equivalence, equivalence margin au non-inferiority analysis. Kwa hiyo, haiwezi kuhitimishwa kwamba BSS ni pharmacologically equivalent na dexamethasone.

LPS na BSS ziliunda cytokine profile ileile?

Hapana. Kielelezo 2 kinaonyesha kwamba microbial stimuli hizi mbili ziliunda tofauti za gene-expression profiles. Watafiti walichunguza mRNA levels za Ifn-α4, Ifn-β1, Il-6 na Il-1β katika peripheral blood mononuclear cells na lung.

LPS, hasa katika 40 µg/kg, iliongeza Ifn-β1 expression; lakini ilionyesha limited effect kwenye Ifn-α4 katika muda uliopimwa. Kwa upande mwingine, 10⁷ na 10⁸ CFU/panya doses za BSS ziliongeza transcription ya Ifn-α4 na Ifn-β1 ndani ya saa nne, na response ikawa wazi zaidi saa ya nane.

Katika proinflammatory cytokines, pattern ya kinyume ilionekana. LPS, hata katika 4 µg/kg, iliongeza Il-6 na Il-1β transcription na ongezeko likawa kubwa zaidi katika 40 µg/kg. BSS, hata katika highest dose, ilisababisha ongezeko la chini ya takribani mara mbili au limited increases kwa jeni hizi mbili.

Katika lung samples pia kulionekana distribution inayolingana na BSS kuchochea type I interferon genes kwa nguvu zaidi na LPS kuchochea proinflammatory genes kwa nguvu zaidi. Hata hivyo, kilichopimwa ni mRNA levels. Utafiti haujaripoti IFN-α, IFN-β, IL-6 na IL-1β protein concentrations katika damu au tissue.

Gene expression ilihesabiwaje?

RT-qPCR analyses zilifanywa technically in triplicate na expression ya target genes ikanormalishwa dhidi ya β-actin mRNA. Relative gene expression ilihesabiwa kwa 2^−ΔΔCt method:

\[ Göreli\ gen\ ifadesi = 2^{-\Delta\Delta Ct} \]

Katika uhusiano huu, Ct ni idadi ya cycles ambapo PCR signal inapita threshold iliyowekwa. Kwanza, tofauti ya Ct kati ya target gene na β-actin huhesabiwa:

\[ \Delta Ct = Ct_{hedef} - Ct_{\beta\text{-aktin}} \]

Kisha ΔCt value ya treatment group hutolewa kutoka ΔCt value ya control group:

\[ \Delta\Delta Ct = \Delta Ct_{tedavi} - \Delta Ct_{kontrol} \]

Result ya 1 inamaanisha expression karibu na control group, 2 takribani mara mbili ya expression, na 0,5 takribani nusu ya expression level. Method inategemea assumption kwamba PCR efficiencies ni sufficiently similar kati ya target na reference genes.

Kwa nini protective effect imehusishwa na IFNAR signaling?

Kielelezo 3 kilitumia panya wasio na IFNAR1 receptor. Katika normal au heterozygous Ifnar1^+/− mice, LPS na BSS zilipunguza Evans blue leakage, ear edema, temperature drop na MCPT-1 level. Katika homozygous Ifnar1^−/− mice, treatments hizo hizo hazikutoa meaningful protection.

Dexamethasone effect ilidumu katika IFNAR1 deficiency. Tofauti hii inaunga mkono kwamba LPS na BSS hufanya kazi kupitia IFNAR-dependent mechanism tofauti na dexamethasone.

Iliripotiwa pia kwamba katika untreated IFNAR1-deficient mice, anaphylaxis response ilikuwa kali zaidi kuliko control mice. Watafiti walitafsiri hili kuwa normal low-level IFNAR signaling inaweza kuwa na regulatory role juu ya mast-cell maturation na activation.

Athari inaweza kutokana na direct suppression ya vascular cells?

Ili kupima uwezekano huu, mast cells zilipitwa na 1 µg serotonin na 10 µg histamine zikatolewa kwenye ngozi ya sikio. Histamine na serotonin zilifanya kazi moja kwa moja kwenye vascular endothelium na kusababisha permeability na edema.

LPS au BSS pretreatment haikupunguza Evans blue leakage wala ear thickening katika model hii. Kwa hiyo, ilihitimishwa kwamba treatments zinafanya kazi katika kiwango cha mast-cell activation kabla ya histamine na mediators wengine kutolewa, badala ya kutoa direct generalized resistance kwa vascular endothelium.

Ingawa jaribio hili linaunga mkono athari juu ya mast cells, haliondoi kikamilifu mchango wa immune-cell types nyingine, neural regulation au systemic metabolic changes.

Mevalonate pathway ni nini na imehusishwaje na mast cells?

Mevalonate pathway ni metabolic network ambapo seli hutengeneza cholesterol na various isoprenoid intermediates. HMG-CoA reductase au HMGCR ni rate-limiting enzyme ya pathway. Enzyme hubadilisha HMG-CoA kuwa mevalonate.

Makundi mawili makuu ya bidhaa yanaweza kutengenezwa kutoka mevalonate. Tawi moja huendelea kwenye synthesis ya cholesterol na sterols nyingine. Tawi jingine hutengeneza non-sterol isoprenoids kama isopentenyl pyrophosphate, farnesyl pyrophosphate na geranylgeranyl pyrophosphate.

FPP na GGPP zinahitajika kwa prenylation, yaani kuongeza lipid groups kwenye protini fulani. Prenylation inaweza kuathiri kufungamana kwa signaling proteins kama small GTPases kwenye cell membrane na kuhamishwa kwao kwenye proper cellular location. Modeli ya utafiti ni kwamba kupungua kwa bidhaa hizi huvuruga actin rearrangement na maendeleo ya FcεRI signaling katika mast cell.

Proposed molecular chain inafanyaje kazi?

Mechanism iliyopendekezwa na watafiti ina mpangilio ufuatao:

1. LPS au BSS huanzisha type I interferon response.
2. IFN-α/β hutoa signal kupitia common receptor IFNAR.
3. Cyp51a1 transcription hupungua katika mast cells.
4. Lanosterol accumulation inadhaniwa kutokea kutokana na kupungua kwa CYP51A1 activity.
5. Lanosterol hupunguza Hmgcr transcription na pengine HMGCR protein stability.
6. Mevalonate production na non-sterol isoprenoid pool hupungua.
7. Prenylation inayohitajika kwa small GTPases na biomolecules nyingine huzuiwa.
8. Cortical F-actin rearrangement katika response ya antigen stimulation huvurugika.
9. Formation ya LAT–PLC-γ1 signaling complex, PLC-γ1 activation na calcium entry kutoka extracellular environment huzuiwa.
10. Mast-cell degranulation na histamine release hupungua.

Si hatua zote za chain hii zimepimwa moja kwa moja katika utafiti mmoja. Main directly measured elements ni Cyp51a1 na Hmgcr mRNA levels, anaphylaxis measures, mast-cell morphology na histamine release. Lanosterol accumulation, isoprenoid reduction, loss of prenylation na actin mechanism zimehitimishwa kutoka intervention experiments.

Cyp51a1 na Hmgcr genes zilibadilikaje?

Kielelezo 4 kinaonyesha kwamba LPS na BSS katika peritoneal mast cells kutoka Ifnar1^+/− mice zilipunguza Cyp51a1 na Hmgcr mRNA levels hadi takribani nusu au chini zaidi. Ifnar1 mRNA level haikuathiriwa na treatments.

Katika IFNAR1-deficient mast cells, LPS au BSS hazikubana jeni hizi mbili. Pia, baseline Cyp51a1 na Hmgcr levels kuwa juu zaidi katika deficient mice kuliko control mice kulipendekeza kwamba basal IFNAR signaling inaweza kutoa continuous suppressive pressure juu ya metabolic genes hizi.

Dexamethasone haikupunguza Cyp51a1 au Hmgcr expression. Finding hii inaonyesha kwamba dexamethasone na microbial stimuli zinaweza kufikia similar phenotypic outcomes kupitia different cellular pathways.

Jaribio la terbinafine lilipima nini?

Terbinafine huzuia squalene epoxidase enzyme. Enzyme hii hufanya kazi katika moja ya hatua za juu za progression ya squalene kuelekea lanosterol synthesis. Watafiti walitoa terbinafine pamoja na LPS au BSS ili kuzuia lanosterol accumulation inayodhaniwa kutokea Cyp51a1 inapobana.

Terbinafine haikuzuia LPS na BSS kupunguza Cyp51a1 mRNA level; lakini ilirejesha Hmgcr expression karibu na control level. Positioning hii ni muhimu: result inaunga mkono kwamba Cyp51a1 suppression iko upstream na Hmgcr suppression inaweza kutegemea lanosterol formation.

Kielelezo 5 kinaonyesha pia kwamba terbinafine iliondoa protective effect ya LPS na BSS dhidi ya cutaneous anaphylaxis. Evans blue leakage na ear edema ziliongezeka tena. Reversal hii haikuonekana katika IFNAR1-deficient mice.

Lanosterol haikupimwa moja kwa moja kwa chemical method katika utafiti. Result ya terbinafine experiment ni indirect pharmacological evidence inayounga mkono role ya lanosterol.

Mevalonate-pathway intermediates zilionyesha nini?

Watafiti walitoa mevalonolactone, farnesol au squalene pamoja na LPS au BSS. Mevalonolactone ni upper intermediate inayohusiana na mevalonate ndani ya seli, farnesol ni compound inayohusiana na non-sterol isoprenoid products, na squalene ni intermediate kabla ya lanosterol katika cholesterol-synthesis branch.

Mevalonolactone na farnesol ziliondoa protective effect ya LPS na BSS dhidi ya anaphylaxis. Kwa upande mwingine, squalene haikureverse protective effect.

Tofauti hii inaunga mkono tafsiri kwamba mast-cell suppression inahusiana zaidi na kupungua kwa non-sterol isoprenoid branch ya mevalonate pathway kuliko final products za cholesterol synthesis. Hata hivyo, intracellular concentrations za IPP, FPP au GGPP hazikupimwa moja kwa moja.

Histology ilionyesha nini katika mast cells?

Kielelezo 6 kinaonyesha mast cells katika ear tissue ya panya zilizopakwa toluidine blue. Katika mice ambazo hazikupewa antigen, seli zilionekana oval, zikiwa na clear boundaries na cytoplasm iliyojazwa dense purple-blue granules. Morphology hii inawakilisha resting mast cell.

Katika antigen-stimulated mice bila treatment, cell boundaries zilionekana kuvurugika, large pale areas zikaonekana katika cytoplasm na granule staining ikapotea. Watafiti waliainisha seli hizi kama cells zinazoonyesha extensive degranulation.

Katika LPS, BSS na dexamethasone groups, pale areas zilikuwa ndogo, cell boundaries zilifuatilika zaidi na granule loss ilikuwa limited zaidi. Ingawa baadhi ya cells zilichukua elongated shape, extensive degranulation appearance ilionekana kidogo zaidi.

Cells ziligawanywa katika makundi matatu: resting, partial degranulation na extensive degranulation. Ili kupunguza misclassification ya cell fragments zilizobaki kwenye edge ya section, mast cells pekee zenye largest cross-sectional diameter ya takribani 15 µm au zaidi ndizo zilitathminiwa.

Katika analysis ya total tissue sections 18, zaidi ya %90 ya mast cells katika mice zisizopewa antigen zilikuwa na resting morphology. Katika untreated antigen group, vast majority ya cells zilionyesha extensive degranulation. Katika LPS na BSS groups, proportion ya cells zilizoonyesha extensive degranulation ilibaki chini ya %20.

Katika IFNAR1-deficient mice, bila kujali treatment, zaidi ya %70 ya mast cells zilionyesha extensive degranulation baada ya antigen. Result hii inaunga mkono kwamba histological protection pia inategemea IFNAR signaling.

Jaribio la cytochalasin D lilipimaje actin mechanism?

Cytochalasin D ni compound inayobadilisha dynamics za actin filaments. Watafiti walichukua peritoneal cells kutoka mice waliopata LPS, BSS au dexamethasone na kuzitreat kwa low-nanomolar cytochalasin D kwa dakika 20 kabla ya kuchochea cells kwa antigen.

Katika cells kutoka wanyama waliotreatiwa kwa LPS na BSS, antigen-triggered histamine release ilikuwa chini. Short-term 20 nM cytochalasin D treatment iliongeza histamine release tena. Reversal hii haikuonekana katika dexamethasone group.

Katika IFNAR1-deficient cells, hakukuwa na LPS- na BSS-specific reversal effect ya cytochalasin D. Findings zinaunga mkono mtazamo kwamba microbial stimuli hubana mast cell kupitia cortical actin dynamics.

Utafiti ulitumia ratio ya released histamine kwa total histamine. Hesabu hii inaweza kuonyeshwa kimsingi kama:

\[ Histamin\ salımı\ (\%) = \frac{H_{süpernatant}}{H_{süpernatant}+H_{hücre\ içi}} \times 100 \]

H_süpernatant inawakilisha histamine iliyotolewa nje ya seli, na H_{hücre içi} histamine iliyobaki ndani ya seli. Dozi ya 20 nM cytochalasin D iliinua ratio hii katika LPS na BSS groups kutoka takribani %30 hadi %45–55 kwenye grafu. Values hizi zimesomwa takribani kutoka kwenye figure.

Kwa nini BSS ilionekana kuwa favorable zaidi kuliko LPS?

Ingawa stimuli zote mbili zilipunguza anaphylaxis measures, cytokine profiles zilikuwa tofauti. BSS ilichochea IFN-α/β genes kwa nguvu huku ikiweka ongezeko la Il-6 na Il-1β kuwa limited. LPS, hasa katika high dose, ilizalisha strong proinflammatory gene transcription.

Waandishi wanajadili kwamba bacterial RNA ndani ya endospore inaweza kutambuliwa na TLR7 au TLR13 katika endosomes baada ya phagocytosis; hali hii inaweza kusukuma mbele MyD88–IRF7 axis na type I interferons. LPS, kwa upande mwingine, inaweza kuanzisha kwa nguvu MyD88–NF-κB signaling kupitia TLR4 kwenye cell surface na kuongeza proinflammatory cytokines kama IL-6 na IL-1β.

Njia hizi za molecular sensing hazikupimwa moja kwa moja katika utafiti huu kwa loss experiments za TLR7, TLR13, TLR4, MyD88, IRF7 au NF-κB. Mechanism katika discussion section ni explanation inayotegemea literature ya awali.

Kauli kwamba BSS “haina hatari ya sepsis-like cytokine release” inazidi mipaka ya data zilizopatikana. Utafiti ulipima tu short-term mRNA response ya genes maalum. Cytokine proteins, fever, blood pressure, organ damage, complete blood count, long-term inflammation au human safety havikutathminiwa.

Nguvu za utafiti ni zipi?

• Modeli mbili tofauti za anaphylaxis inayoendeshwa na IgE zilitumika: systemic na cutaneous.
• Vipimo vinavyokamilishana kama body temperature, MCPT-1, vascular leakage, edema, histology na histamine release vilichunguzwa.
• Receptor dependence ilipimwa kijeni kwa kutumia IFNAR1-deficient mice.
• Control experiment iliyopitisha mast cell kwa kutumia serotonin na histamine ilifanywa.
• Hatua tofauti za metabolic pathway ziliingiliwa kwa kutumia terbinafine, mevalonolactone, farnesol na squalene.
• Mast-cell morphology ilitathminiwa ndani ya tissue na degranulation ikaainishwa.
• Cytochalasin D experiment ilipima mechanism inayohusiana na actin dynamics kwa functional reversal approach.
• Interferon na proinflammatory cytokine profiles za LPS na BSS zililinganishwa.

Mapungufu muhimu ya utafiti ni yapi?

• Utafiti ulifanywa kwa panya dume wa wiki 6–10 pekee; wanyama jike na age groups tofauti hawakutathminiwa.
• Passive anaphylaxis models haziwakilishi natural sensitization process na biolojia yote ya human allergic diseases.
• LPS na BSS zilitolewa kwa siku mbili kabla ya reaction. Utafiti haukuchunguza emergency treatment ya anaphylaxis iliyokuwa tayari imeanza.
• Total animal numbers katika experimental groups hazikutolewa kwa uwazi na kwa pamoja katika methods section.
• Random group assignment, researcher blinding na a priori power analysis hazikuripotiwa.
• Ingawa RT-qPCR ilifanywa technically in triplicate, independent biological replicate numbers hazikuwasilishwa wazi kwa experiments zote.
• Type I interferons na proinflammatory cytokines hazikupimwa katika protein level.
• Lanosterol, HMGCR protein, IPP, FPP, GGPP na protein prenylation hazikupimwa moja kwa moja.
• Cortical F-actin dynamics hazikuonyeshwa moja kwa moja katika live mast cells.
• LAT–PLC-γ1 complexes, PLC-γ1 phosphorylation na calcium entry hazikupimwa katika utafiti huu.
• Kwa BSS, long-term toxicity, repeat dosing, spore germination, tissue distribution na immunogenicity hazikutathminiwa.
• Hakuna human data kuhusu usalama wa intranasal LPS.
• Similarity na dexamethasone haikuonyeshwa kwa formal equivalence test.
• Maandishi yanasema “nonparametric one-way ANOVA” ikifuatiwa na Tukey multiple-comparison test. Haiko wazi kama test iliyotumika ilikuwa classical parametric one-way ANOVA au nonparametric approach nyingine.
• Supplementary Figures S1–S3 zilizorejelewa katika utafiti hazipo katika main version iliyochunguzwa; kwa hiyo baadhi ya supporting analyses hazikuweza kuthibitishwa visually.
• Hakuna clear data-availability statement kuhusu data sharing.

Matokeo yanayoungwa mkono na utafiti

• Intranasal pretreatment ya LPS na BSS ilipunguza IgE-mediated systemic na cutaneous anaphylaxis measures katika mouse models zilizotumika.
• Protective effect ya LPS na BSS inategemea uwepo wa IFNAR1 signaling.
• Treatments zilipunguza Cyp51a1 na Hmgcr mRNA levels katika mast cells kwa IFNAR-dependent manner.
• Terbinafine, mevalonolactone na farnesol interventions zilireverse protective phenotype.
• Squalene kutoreverse protective effect kuliunga mkono umuhimu wa non-sterol mevalonate products.
• LPS na BSS zilipunguza proportion ya extensive degranulation katika tissue mast cells.
• Low-dose cytochalasin D iliongeza tena histamine release iliyokuwa imebanwa baada ya LPS na BSS.
• BSS ilizalisha lower Il-6 na Il-1β response kuliko LPS katika short-term gene-expression measurements zilizochunguzwa.

Matokeo ambayo utafiti hauungi mkono au kuthibitisha

• Haijaonyeshwa kwamba BSS au LPS huzuia au kutibu anaphylaxis kwa binadamu.
• Haijathibitishwa kwamba intranasal administration ya endospores au LPS ni salama kwa binadamu.
• Haijaonyeshwa kwamba BSS haitasababisha sepsis, fever au systemic adverse effects nyingine.
• Utafiti hautoi evidence ya clinical success katika asthma, food allergy au atopic dermatitis.
• BSS haijatathminiwa kama alternative ya standard emergency anaphylaxis treatments.
• Haijathibitishwa clinically kwamba endospores zinaweza kutumiwa kupitia pua kama “probiotic”.
• Haijaonyeshwa kwa direct biochemical measurement kwamba intermediates zote za mevalonate pathway zimepungua kweli.
• Protein prenylation na cortical F-actin regulation hazijathibitishwa kwa direct molecular imaging.
• Haijaonyeshwa kwamba low allergy risk kwa watu wanaoishi katika farm environment inaweza kuelezwa kwa mechanism hii pekee.
• Haijaonyeshwa kwamba pretreatment ya siku mbili inazalisha long-term allergy protection.

Ni uthibitishaji gani unahitajika baadaye?

Katika hatua inayofuata, experiments zinazojumuisha female na male animals, kurudiwa katika independent laboratories na preregistered zinahitajika. Natural sensitization models, food allergy, asthma na atopic dermatitis disease models tofauti zinapaswa kupimwa kila moja.

Ili kuimarisha proposed mechanism, IFN-α/β protein levels, lanosterol na mevalonate-pathway metabolites, HMGCR protein amount, small GTPase prenylation, F-actin dynamics, PLC-γ1 activation na calcium flux zinapaswa kupimwa moja kwa moja.

Ikiwa development ya BSS itazingatiwa, safety issues kama endospore purity, germination capability, genetic stability, tissue distribution, lung histology, repeated-dose toxicity, immunogenicity na clearance ya spores kutoka mazingira zinapaswa kuchunguzwa.

Kabla ya kuhamia human studies, appropriate pharmaceutical form, dose, administration frequency na reversible adverse effects zinapaswa kuamuliwa. Current results hazitoshi kufanya clinical-use decision.

Mbinu na Matokeo ya Utafiti

Research model

Main doses na experimental conditions

Experimental measures

Scientific message ya figures

Direct na indirect steps za evidence chain

Statistical assessment

Waandishi walifanya analyses kwa GraphPad Prism 6 na walisema walitumia “nonparametric one-way ANOVA” kwa differences kati ya multiple groups, ikifuatiwa na Tukey multiple-comparison test. Statistical significance threshold ni p < 0,05.

Kauli hii si wazi vya kutosha kwa upande wa methodology. Classical one-way ANOVA ni parametric test; common nonparametric counterpart yake ni Kruskal–Wallis test na kwa kawaida huunganishwa na post hoc test kama Dunn, si Tukey. Utafiti hauelezi exact software option iliyotumika, normality test au variance assumption.

Ingawa individual data points zinaonyeshwa kwenye grafu, animal numbers, effect sizes, confidence intervals na exact p values kwa experiments zote hazijatolewa kwa pamoja katika maandishi. Upungufu huu hufanya tathmini ya reproducibility na statistical power ya results kuwa ngumu.

Maelezo ya Chanzo na Mbinu

Jina kamili la asili la utafiti:Microbial endospores protect against anaphylaxis via interferon-α/β–induced mevalonate pathway inhibition and cortical F-actin stabilization in mast cells

Waandishi na mpangilio wao: Liu Ye, Rema Naskar na Inkyu Hwang.

Taarifa ya equal contribution: Kuna asterisk karibu na jina la Liu Ye; hata hivyo, maelezo ya alama hiyo hayapo katika version iliyochunguzwa. Equal first authorship haijathibitishwa.

Mwandishi wa mawasiliano: Inkyu Hwang, Ph.D.; hwanginkyu@cnu.ac.kr.

Maelezo ya mawasiliano ya waandishi wengine: Liu Ye: liuye1995@naver.com; Rema Naskar: rema.naskar@gmail.com.

Taasisi: Laboratory of Immunology and Immunopharmacology, College of Pharmacy, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon 34134, South Korea.

DOI: 10.2139/ssrn.6953967.

Jarida: Haijathibitishwa kwamba imechapishwa au kukubaliwa katika peer-reviewed journal.

Jukwaa la uchapishaji: SSRN.

Mchapishaji asilia: Hakuna peer-reviewed journal publisher. Utafiti umechapishwa kwenye SSRN early-research platform.

Mwaka wa uchapishaji: 2026.

Aina ya chanzo: Preprint animal study inayounganisha in vivo passive anaphylaxis experiments katika mice, genetic IFNAR1 deficiency, pharmacological pathway interventions, tissue histology na ex vivo mast-cell function tests.

Hali ya mapitio ya kitaalamu: Utafiti huu ni preprint ambayo haijapitia peer review; results zake zinapaswa kusomwa kwa kuzingatia limitation hii.

Kiungo rasmi:Rekodi rasmi ya utafiti ya SSRN

Michango ya waandishi: Liu Ye alifanya research, formal analysis na data curation; Rema Naskar research, formal analysis na data curation; Inkyu Hwang writing of original manuscript, supervision, funding acquisition, data curation na conceptualization.

Ufadhili: Utafiti ulifadhiliwa na National Research Foundation of Korea kupitia grants NRF-2019R1F1A1061894 na NRF-2019M3A9G4067293; na Chungnam National University kupitia grants 2024–1076-01 na 2022–0663-01. Imeelezwa kwamba Rema Naskar na Liu Ye walipata support kutoka BK21 Four na CNU-Star Fellowship programs.

Mgongano wa maslahi: Waandishi hawakuripoti known financial interest au personal relationship inayoweza kuathiri utafiti.

Ethics approval: Animal experiments ziliidhinishwa na Chungnam National University Institutional Animal Care and Use Committee kwa protocol number CNU-00996.

Makala haya ya Kituruki yameandaliwa kwa kupitia main text, methods, experimental conditions, gene expressions, pharmacological interventions, histology images na figures sita kuu za utafiti uliopakiwa. Scientific narrative imewekewa mipaka na data pamoja na interpretations za waandishi zilizowasilishwa na utafiti, na hakuna new scientific finding kutoka external sources iliyoongezwa. External check ilitumika tu kwa bibliographic verification ya title, DOI, platform na publication status.

Utafiti si evidence ya clinical effect kwa binadamu. Haupendekezi intranasal administration ya LPS au bacterial endospores zenye uwezo wa kuonyesha viability. LPS ni strong microbial inflammatory stimulus na imeongeza proinflammatory genes katika results za utafiti wenyewe. Lower short-term cytokine transcription iliyoripotiwa kwa BSS haimaanishi comprehensive safety au approval ya matumizi kwa binadamu.

Mapungufu makuu ya utafiti ni matumizi ya male mice pekee, passive anaphylaxis models, preventive administration design, kutoripoti group sizes kwa uwazi, kukosekana kwa long-term safety data, kutopimwa kwa cytokines na metabolites katika protein/chemical level, baadhi ya hatua za mechanism kutegemea indirect inference, statistical method kuandikwa kwa ambiguity na supplementary figures kutokuwepo katika version iliyochunguzwa.